Literature DB >> 8037754

Constrained analogues of the calcitonin gene-related peptide.

J M Hakala1, T Valo, S Vihavainen, J Hermonen, P Heino, M Halme, A M Koskinen.   

Abstract

The calcitonin gene-related peptide, CGRP, has potential medicinal use for instance as a vasodilator or in the regulation of bone metabolism. In this study new analogues of CGRP based on molecular modelling of active fragments were synthesised and tested. The analogues were found to have affinities for the receptor comparable to those seen for native CGRP. Two analogues were found to be agonists. The analogues give an insight to the bioactive conformation of CGRP as they were constrained by disulphide bridges.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8037754     DOI: 10.1006/bbrc.1994.1956

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Conformational restraints revealing bioactive beta-bend structures for halpha CGRP8-37 at the CGRP2 receptor of the rat prostatic vas deferens.

Authors:  F M Wisskirchen; P M Doyle; S L Gough; C J Harris; I Marshall
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

2.  Bioactive beta-bend structures for the antagonist halpha CGRP(8 - 37) at the CGRP(1) receptor of the rat pulmonary artery.

Authors:  F M Wisskirchen; P M Doyle; S L Gough; C J Harris; I Marshall
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 3.  Structure-activity relationships for α-calcitonin gene-related peptide.

Authors:  Harriet A Watkins; Dan L Rathbone; James Barwell; Debbie L Hay; David R Poyner
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Structure-activity relationships of the N-terminus of calcitonin gene-related peptide: key roles of alanine-5 and threonine-6 in receptor activation.

Authors:  Debbie L Hay; Paul W R Harris; Renata Kowalczyk; Margaret A Brimble; Dan L Rathbone; James Barwell; Alex C Conner; David R Poyner
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.